Zura Bio ZURA 深 滬
等待開盤 01-13 09:30:00 美东时间
5.16
+0.040
+0.78%
華盛通- 最 高5.25
- 今 開5.12
- 成交量 53.76万股
- 最 低 4.7501
- 昨 收 5.12
- 總市值 3.36亿
- 52周最高 5.75
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.97
- 委 比 36.88%
- 總股本 6502.33万
- 歷史最高 37.55
- 量 比 0.79
- 振 幅 9.76%
- 歷史最低 0.97
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zura Bio Updates Outlook and Clinical Development Plans
The latest announcement is out from Zura Bio ( ($ZURA) ). On January 12, 2026, ...
01-12 20:20
Zura Bio Targets Key 2026–2027 Trial Readouts as Lead Autoimmune Drug Advances, Eyes Transformational Data in 2026 as Tibulizumab Studies Progress
Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
01-12 19:32
Zura Bio resets key agreements after internal review
An announcement from Zura Bio ( ($ZURA) ) is now available. On December 29, 202...
01-03 05:49
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock increased by 25.5% to $25.9...
2025-12-30 01:05
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points ...
2025-12-29 23:30
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Zura Bio Q4 EPS $(0.21) Misses $(0.18) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 15.38 percent. This is a 19.23 percent increase over losses of $(0.26) per share from the
2025-11-13 19:32
Clear Street Initiates Coverage On Zura Bio with Buy Rating, Announces Price Target of $18
Clear Street analyst Kaveri Pohlman initiates coverage on Zura Bio (NASDAQ:ZURA) with a Buy rating and announces Price Target of $18.
2025-11-13 19:12
美股牛股 | ANAB大涨超31%！宣布重大业务重组计划；Wolfspeed再涨超29%，宣布脱离破产保护
ANAB大涨超31%！宣布重大业务重组计划；Wolfspeed再涨超29%，宣布脱离破产保护；MFH昨日涨近26%，美国SEC释放监管利好信号>>
2025-10-01 20:34
